1BP-LSD

1BP-LSD
Clinical data
Other names1-(3-(Tetramethyldioxa-borolane)propionyl)-LSD
Routes of
administration		Oral[1]
Drug classSerotonergic psychedelic; Hallucinogen
ATC code
  • None
Identifiers
  • (6aR,9R)-N,N-diethyl-7-methyl-4-(4-(4,4,5,5-tetraethyl-1,3,2-dioxaborolan-2-yl)benzoyl)-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide
Chemical and physical data
FormulaC37H48BN3O4
Molar mass609.62 g·mol−1
3D model (JSmol)
  • CCN(C([C@H](C=C1[C@@]2([H])CC3=CN(C(CCB4OC(C)(C)C(C)(C)O4)=O)C5=CC=CC1=C35)CN2C)=O)CC
  • InChI=1S/C29H40BN3O4/c1-8-32(9-2)27(35)20-15-22-21-11-10-12-23-26(21)19(16-24(22)31(7)17-20)18-33(23)25(34)13-14-30-36-28(3,4)29(5,6)37-30/h10-12,15,18,20,24H,8-9,13-14,16-17H2,1-7H3/t20-,24-/m1/s1
  • Key:WTJNMHVFTSXKOI-HYBUGGRVSA-N

1BP-LSD, also known as 1-(3-(tetramethyldioxaborolane)propionyl)-LSD, is a psychedelic drug of the lysergamide family related to lysergic acid diethylamide (LSD).[1] It is thought to be a prodrug of LSD.[1] The drug was encountered online as a novel designer drug in December 2025.[1] 1BP-LSD has been sold in the form of blotter containing 175 and 200 μg per tab.[1] It has been said to be considered to be the official legal successor of 1S-LSD, which was banned in Germany soon before 1BP-LSD's appearance.[1] The effects of 1BP-LSD are said to be similar to those of 1S-LSD and to include visual changes, altered perception of time and space, heightened emotions, and increased creativity.[1] 1BP-LSD is not an explicitly controlled substance in the United States[2] or in Canada.[3]

See also

References

  1. ^ a b c d e f g "1BP-LSD". АИПСИН (in Russian). Retrieved 5 January 2026.
  2. ^ Orange Book: List of Controlled Substances and Regulated Chemicals (January 2026) (PDF), United States: U.S. Department of Justice: Drug Enforcement Administration (DEA): Diversion Control Division, January 2026
  3. ^ "Controlled Drugs and Substances Act". Department of Justice Canada. 5 December 2025. Retrieved 20 January 2026.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.